Dr Luke Gammon - Publications
1: Wallis R, Hughes BK, Moore M, O'Sullivan EA, McIlvenna LC, Gammon L, Hope A,
Bellany F, Dixit P, Mackenzie C, Green C, Gray D, Bishop CL. SAMP-Score: a
morphology-based machine learning classification method for screening pro-
senescence compounds in p16 positive cancer cells. Aging (Albany NY). 2025 Oct
30;17(11):2688-2716. doi: 10.18632/aging.206333. Epub 2025 Oct 30. PMID:
41182172; PMCID: PMC12822720.
2: Knowles O, Doldan P, Hillier-Richardson I, Lunetto S, Lunt S, Youssef G,
Gammon L, Mackenzie IC, Philpott MP, Rizvi H, Bergamaschi D, Harwood CA, Biddle
A. A CD24<sup>+</sup>CD271<sup>+</sup> melanoma cancer stem cell possesses
hybrid characteristics of its single marker counterparts and promotes invasion
and therapeutic resistance. BMC Biol. 2025 Aug 4;23(1):235. doi:
10.1186/s12915-025-02336-2. PMID: 40754577; PMCID: PMC12320275.
3: Youssef G, Gammon L, Ambler L, Lunetto S, Scemama A, Cottom H, Piper K,
Mackenzie IC, Philpott MP, Biddle A. Disseminating cells in human oral tumours
possess an EMT cancer stem cell marker profile that is predictive of metastasis
in image-based machine learning. Elife. 2023 Nov 17;12:e90298. doi:
10.7554/eLife.90298. PMID: 37975646; PMCID: PMC10781423.
4: Murray A, Gough G, Cindrić A, Vučković F, Koschut D, Borelli V, Petrović DJ,
Bekavac A, Plećaš A, Hribljan V, Brunmeir R, Jurić J, Pučić-Baković M, Slana A,
Deriš H, Frkatović A, Groet J, O'Brien NL, Chen HY, Yeap YJ, Delom F, Havlicek
S, Gammon L, Hamburg S, Startin C, D'Souza H, Mitrečić D, Kero M, Odak L,
Krušlin B, Krsnik Ž, Kostović I, Foo JN, Loh YH, Dunn NR, de la Luna S, Spector
T, Barišić I, Thomas MSC, Strydom A, Franceschi C, Lauc G, Krištić J, Alić I,
Nižetić D. Dose imbalance of DYRK1A kinase causes systemic progeroid status in
Down syndrome by increasing the un-repaired DNA damage and reducing LaminB1
levels. EBioMedicine. 2023 Aug;94:104692. doi: 10.1016/j.ebiom.2023.104692. Epub
2023 Jul 12. PMID: 37451904; PMCID: PMC10435767.
5: Palmer A, Epton S, Crawley E, Straface M, Gammon L, Edgar MM, Xu Y, Elahi S,
Chin-Aleong J, Martin JE, Bishop CL, Knowles CH, Sanger GJ. Expression of p16
Within Myenteric Neurons of the Aged Colon: A Potential Marker of Declining
Function. Front Neurosci. 2021 Oct 7;15:747067. doi: 10.3389/fnins.2021.747067.
PMID: 34690683; PMCID: PMC8529329.
6: Huang Y, Jedličková H, Cai Y, Rehman A, Gammon L, Ahmad US, Uttagomol J,
Parkinson EK, Fortune F, Wan H. Oxidative Stress-Mediated YAP Dysregulation
Contributes to the Pathogenesis of Pemphigus Vulgaris. Front Immunol. 2021 Apr
19;12:649502. doi: 10.3389/fimmu.2021.649502. PMID: 33968042; PMCID: PMC8098436.
7: Almeida FV, Gammon L, Laly AC, Pundel OJ, Bishop CL, Connelly JT. High-
Content Analysis of Cell Migration Dynamics within a Micropatterned Screening
Platform. Adv Biosyst. 2019 Aug;3(8):e1900011. doi: 10.1002/adbi.201900011. Epub
2019 Jun 13. PMID: 32648701.
8: Patel A, Garcia LF, Mannella V, Gammon L, Borg TM, Maffucci T, Scatolini M,
Chiorino G, Vergani E, Rodolfo M, Maurichi A, Posch C, Matin RN, Harwood CA,
Bergamaschi D. Targeting p63 Upregulation Abrogates Resistance to MAPK
Inhibitors in Melanoma. Cancer Res. 2020 Jun 15;80(12):2676-2688. doi:
10.1158/0008-5472.CAN-19-3230. Epub 2020 Apr 14. PMID: 32291316.
9: Ali L, Saxena G, Jones M, Leisegang GR, Gammon L, Gnanapavan S, Giovannoni G,
Schmierer K, Baker D, Kang AS. A cell-based assay for the detection of
neutralizing antibodies against alemtuzumab. Biotechniques. 2020
Apr;68(4):185-190. doi: 10.2144/btn-2019-0122. Epub 2020 Feb 25. PMID: 32096651;
PMCID: PMC7177201.
10: Setúbal Destro Rodrigues MF, Gammon L, Rahman MM, Biddle A, Nunes FD,
Mackenzie IC. Effects of Cetuximab and Erlotinib on the behaviour of cancer stem
cells in head and neck squamous cell carcinoma. Oncotarget. 2018 Feb
5;9(17):13488-13500. doi: 10.18632/oncotarget.24416. PMID: 29568372; PMCID:
PMC5862593.
11: Nijhuis A, Thompson H, Adam J, Parker A, Gammon L, Lewis A, Bundy JG, Soga
T, Jalaly A, Propper D, Jeffery R, Suraweera N, McDonald S, Thaha MA, Feakins R,
Lowe R, Bishop CL, Silver A. Remodelling of microRNAs in colorectal cancer by
hypoxia alters metabolism profiles and 5-fluorouracil resistance. Hum Mol Genet.
2017 Apr 15;26(8):1552-1564. doi: 10.1093/hmg/ddx059. PMID: 28207045; PMCID:
PMC5393147.
12: Biddle A, Gammon L, Liang X, Costea DE, Mackenzie IC. Phenotypic Plasticity
Determines Cancer Stem Cell Therapeutic Resistance in Oral Squamous Cell
Carcinoma. EBioMedicine. 2016 Jan 9;4:138-45. doi: 10.1016/j.ebiom.2016.01.007.
PMID: 26981578; PMCID: PMC4776071.
13: Gemenetzidis E, Gammon L, Biddle A, Emich H, Mackenzie IC. Invasive oral
cancer stem cells display resistance to ionising radiation. Oncotarget. 2015 Dec
22;6(41):43964-77. doi: 10.18632/oncotarget.6268. PMID: 26540568; PMCID:
PMC4791279.
14: Gammon L, Mackenzie IC. Roles of hypoxia, stem cells and epithelial-
mesenchymal transition in the spread and treatment resistance of head and neck
cancer. J Oral Pathol Med. 2016 Feb;45(2):77-82. doi: 10.1111/jop.12327. Epub
2015 May 7. PMID: 25952002.
15: Shigeishi H, Biddle A, Gammon L, Rodini CO, Yamasaki M, Seino S, Sugiyama M,
Takechi M, Mackenzie IC. Elevation in 5-FU-induced apoptosis in head and neck
cancer stem cells by a combination of CDHP and GSK3β inhibitors. J Oral Pathol
Med. 2015 Mar;44(3):201-7. doi: 10.1111/jop.12230. Epub 2014 Aug 28. PMID:
25169655.
16: Shigeishi H, Biddle A, Gammon L, Emich H, Rodini CO, Gemenetzidis E, Fazil
B, Sugiyama M, Kamata N, Mackenzie IC. Maintenance of stem cell self-renewal in
head and neck cancers requires actions of GSK3β influenced by CD44 and RHAMM.
Stem Cells. 2013 Oct;31(10):2073-83. doi: 10.1002/stem.1418. PMID: 23649588.
17: Gammon L, Biddle A, Heywood HK, Johannessen AC, Mackenzie IC. Sub-sets of
cancer stem cells differ intrinsically in their patterns of oxygen metabolism.
PLoS One. 2013 Apr 30;8(4):e62493. doi: 10.1371/journal.pone.0062493. PMID:
23638097; PMCID: PMC3640080.
18: Biddle A, Gammon L, Fazil B, Mackenzie IC. CD44 staining of cancer stem-like
cells is influenced by down-regulation of CD44 variant isoforms and up-
regulation of the standard CD44 isoform in the population of cells that have
undergone epithelial-to-mesenchymal transition. PLoS One. 2013;8(2):e57314. doi:
10.1371/journal.pone.0057314. Epub 2013 Feb 20. PMID: 23437366; PMCID:
PMC3577706.
19: Tsang SM, Brown L, Gadmor H, Gammon L, Fortune F, Wheeler A, Wan H.
Desmoglein 3 acting as an upstream regulator of Rho GTPases, Rac-1/Cdc42 in the
regulation of actin organisation and dynamics. Exp Cell Res. 2012 Nov
1;318(18):2269-83. doi: 10.1016/j.yexcr.2012.07.002. Epub 2012 Jul 13. PMID:
22796473; PMCID: PMC4022105.
20: Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H, Costea DE,
Mackenzie IC. Cancer stem cells in squamous cell carcinoma switch between two
distinct phenotypes that are preferentially migratory or proliferative. Cancer
Res. 2011 Aug 1;71(15):5317-26. doi: 10.1158/0008-5472.CAN-11-1059. Epub 2011
Jun 17. PMID: 21685475.
21: Gammon L, Biddle A, Fazil B, Harper L, Mackenzie IC. Stem cell
characteristics of cell sub-populations in cell lines derived from head and neck
cancers of Fanconi anemia patients. J Oral Pathol Med. 2011 Feb;40(2):143-52.
doi: 10.1111/j.1600-0714.2010.00972.x. Epub 2010 Dec 8. PMID: 21138479.
22: Harper LJ, Costea DE, Gammon L, Fazil B, Biddle A, Mackenzie IC. Normal and
malignant epithelial cells with stem-like properties have an extended G2 cell
cycle phase that is associated with apoptotic resistance. BMC Cancer. 2010 Apr
28;10:166. doi: 10.1186/1471-2407-10-166. PMID: 20426848; PMCID: PMC2868812.
23: Chamcheu JC, Lorié EP, Akgul B, Bannbers E, Virtanen M, Gammon L, Moustakas
A, Navsaria H, Vahlquist A, Törmä H. Characterization of immortalized human
epidermolysis bullosa simplex (KRT5) cell lines: trimethylamine N-oxide protects
the keratin cytoskeleton against disruptive stress condition. J Dermatol Sci.
2009 Mar;53(3):198-206. doi: 10.1016/j.jdermsci.2008.11.003. Epub 2009 Jan 20.
PMID: 19157792.
24: Costea DE, Gammon L, Kitajima K, Harper L, Mackenzie IC. Epithelial stem
cells and malignancy. J Anat. 2008 Jul;213(1):45-51. doi:
10.1111/j.1469-7580.2008.00895.x. PMID: 18638069; PMCID: PMC2475555.
25: Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, Elia G,
Jeffery R, Leigh IM, Navsaria H, McGrath JA. Potential of fibroblast cell
therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2008
Sep;128(9):2179-89. doi: 10.1038/jid.2008.78. Epub 2008 Apr 3. PMID: 18385758.